Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line

Wang,Fengli; Li,Qiongshu; Ni,Weihua; Fang,Fang; Sun,Xiaxia; Xie,Fei; Wang,Juan; Wang,Fang; Gao,Sujun; Tai,Guixiang

doi:10.3892/or.2013.2440

Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line

Authors:
- Fengli Wang
- Qiongshu Li
- Weihua Ni
- Fang Fang
- Xiaxia Sun
- Fei Xie
- Juan Wang
- Fang Wang
- Sujun Gao
- Guixiang Tai
View Affiliations

Affiliations: Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, P.R. China, Department of Hematology and Oncology, The First Bethune Hospital of Jilin University, Changchun 130021, P.R. China
Published online on: April 30, 2013 https://doi.org/10.3892/or.2013.2440
Pages: 260-268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mucin 1 (MUC1) is a large transmembrane glycoprotein that is aberrantly overexpressed in most adenocarcinomas and certain hematological malignancies. MUC1 is known to function as an oncogene with roles in both tumor formation and progression, making it a potential target for immunotherapy. B16-MUC1 cells with human full-length MUC1 are frequently used to study the antitumor activities of MUC1-based vaccines. However, we found that the growth of B16-MUC1 cells was significantly reduced in vitro. Therefore, in this study, we established two MUC1-positive clones, B16-MUC1 9-12 and B16-MUC1 9-23, and one empty vector control clone, B16-neo, to investigate the effects of MUC1 on the cancer-related characteristics of B16 cells in vitro and in vivo. Our results demonstrated that, compared with MUC1-negative cells, cells expressing MUC1 exhibited decreased cell proliferation, increased cell cycle arrest and reduced cell migratory and invasive capacities. We further investigated several MUC1-related molecules of the β-catenin pathway, and found that the expression of MUC1 decreased the translocation of β-catenin into the nucleus, reduced the activity of T cell factor (TCF) and blocked the expression of cyclin D1 and c-Myc. Moreover, when inoculated into BALB/c nude mice, cells expressing MUC1 developed smaller tumors compared with the control cells. These results demonstrate that MUC1 expression negatively affects the malignancy of B16 cells, and suggest that the regulatory mechanisms of MUC1 as an oncoprotein are more complex than previously appreciated.

View Figures

View References

1	Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
2	Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchel J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 263:12820–12823. 1988.PubMed/NCBI
3	Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV and Hilkens J: Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem. 267:6171–6177. 1992.PubMed/NCBI
4	Kufe DW: Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther. 7:81–84. 2008. View Article : Google Scholar : PubMed/NCBI
5	Li Y, Bharti A, Chen D, Gong J and Kufe D: Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol. 18:7216–7224. 1998.PubMed/NCBI
6	Li Y, Kuwahara H, Ren J, Wen G and Kufe D: The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem. 276:6061–6064. 2001. View Article : Google Scholar : PubMed/NCBI
7	Ren J, Li Y and Kufe D: Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem. 277:17616–17622. 2002. View Article : Google Scholar : PubMed/NCBI
8	Raina D, Ahmad R, Kumar S, et al: MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 25:3774–3783. 2006. View Article : Google Scholar : PubMed/NCBI
9	Wei X, Xu H and Kufe D: Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 7:167–178. 2005. View Article : Google Scholar : PubMed/NCBI
10	Wei X, Xu H and Kufe D: MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell. 21:295–305. 2006. View Article : Google Scholar : PubMed/NCBI
11	Wei X, Xu H and Kufe D: Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 67:1853–1858. 2007. View Article : Google Scholar : PubMed/NCBI
12	Yamamoto M, Bharti A, Li Y and Kufe D: Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem. 272:12492–12494. 1997. View Article : Google Scholar : PubMed/NCBI
13	Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 65:10413–10422. 2005. View Article : Google Scholar : PubMed/NCBI
14	Ahmad R, Raina D, Trivedi V, et al: MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signaling. Nat Cell Biol. 9:1419–1427. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hu XF, Yang E, Li J and Xing PX: MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther. 6:1261–1271. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kufe DW: Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 8:1197–1203. 2009. View Article : Google Scholar : PubMed/NCBI
17	Shin CY, Park KH, Ryu BK, Choi EY, Kim KC and Ko KH: Squamous differentiation downregulates Muc1 mucin in hamster tracheal surface epithelial cell. Biochem Biophys Res Commun. 271:641–646. 2000. View Article : Google Scholar : PubMed/NCBI
18	Ligtenberg MJ, Buijs F, Vos HL and Hilkens J: Suppression of cellular aggregation by high levels of episialin. Cancer Res. 52:2318–2324. 1992.PubMed/NCBI
19	Wesseling J, van der Valk SW, Vos HL, Sonnenberg A and Hilkens J: Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 129:255–265. 1995. View Article : Google Scholar : PubMed/NCBI
20	Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K and Hollingsworth MA: Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer. 88:507–518. 2000. View Article : Google Scholar : PubMed/NCBI
21	Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G and Hugh JC: The breast mucin MUC1 as a novel adhesion ligand for endothelial intracellular adhesion molecule 1 in breast cancer. Cancer Res. 56:4244–4249. 1996.PubMed/NCBI
22	Agrawal B and Longenecker BM: MUC1 mucin-mediated regulation of human T cells. Int Immunol. 17:391–399. 2005. View Article : Google Scholar : PubMed/NCBI
23	Li Y, Liu D, Chen D, Kharbanda S and Kufe D: Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 22:6107–6110. 2003. View Article : Google Scholar : PubMed/NCBI
24	Huang L, Ren J, Chen D, Li Y, Kharbanda S and Kufe D: MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther. 2:702–706. 2003. View Article : Google Scholar : PubMed/NCBI
25	Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S and Kufe D: MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther. 7:1959–1967. 2008. View Article : Google Scholar : PubMed/NCBI
26	Li Y, Ahmad R, Kosugi M, et al: Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 78:166–174. 2010. View Article : Google Scholar : PubMed/NCBI
27	Raina D, Kosugi M, Ahmad R, et al: Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 10:806–816. 2011. View Article : Google Scholar : PubMed/NCBI
28	Schroeder JA, Adriance MC, Thompson MC, Camenisch TD and Gendler SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene. 22:1324–1332. 2003. View Article : Google Scholar : PubMed/NCBI
29	Hattrup CL and Gendler SJ: MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res. 8:R372006. View Article : Google Scholar : PubMed/NCBI
30	Costa NR, Paulo P, Caffrey T, Hollingsworth MA and Santos-Silva F: Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. PLoS One. 6:e269702011. View Article : Google Scholar : PubMed/NCBI
31	Yuan Z, Liu X, Wong S, Machan JT and Chung MA: MUC1 knockdown with RNA interference inhibits pancreatic cancer growth. J Surg Res. 157:e39–e46. 2009. View Article : Google Scholar : PubMed/NCBI
32	Schroeder JA, Masri AA, Adriance MC, et al: MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene. 23:5739–5747. 2004. View Article : Google Scholar : PubMed/NCBI
33	Brossart P, Schneider A, Dill P, et al: The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61:6846–6850. 2001.PubMed/NCBI
34	Yuan Z, Wong S, Borrelli A and Chung MA: Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun. 362:740–746. 2007. View Article : Google Scholar : PubMed/NCBI
35	Gao J, McConnell MJ, Yu B, et al: MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol. 35:337–345. 2009.PubMed/NCBI
36	Kufe D: Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene. 29:5663–5666. 2010. View Article : Google Scholar : PubMed/NCBI
37	Retterspitz MF, Mönig SP, Schreckenberg S, et al: Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res. 30:4635–4641. 2010.
38	Lillehoj EP, Lu W, Kiser T, Goldblum SE and Kim KC: MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism. Biochim Biophys Acta. 1773:1028–1038. 2007. View Article : Google Scholar : PubMed/NCBI
39	Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI
40	Sutherland RL and Musgrove EA: Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 4:14–17. 2002. View Article : Google Scholar : PubMed/NCBI
41	Lavergne E, Hendaoui I, Coulouarn C, et al: Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin. Oncogene. 30:423–433. 2011.PubMed/NCBI
42	Wijnhoven BP, Dinjens WN and Pignatelli M: E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg. 87:992–1005. 2000. View Article : Google Scholar : PubMed/NCBI
43	Premaratne P, Welén K, Damber JE, Hansson GC and Bäckström M: O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model. Tumour Biol. 32:203–213. 2011. View Article : Google Scholar
44	Cascio S, Zhang L and Finn OJ: MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. J Biol Chem. 286:42248–42256. 2011.PubMed/NCBI
45	Spicer AP, Parry G, Patton S and Gendler SJ: Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem. 266:15099–15109. 1991.PubMed/NCBI